Skip to main content
2024 State-of-the Art Clinical Symposium Main banner
Final Program


Schedule at a Glance
Back

Checkpoint Inhibitor Complications of the Rheumatologists

Saturday, April 13, 2024
3:30 PM – 4:00 PM Central Time

    Moderator(s)

  • Kevin Byram, MD

    Vanderbilt University Medical Center
    Nashville, TN, United States

    Disclosure(s): Hemoshear Therapeutics: Consultant (Terminated, August 10, 2023)

    • Speaker(s)

  • Anne Bass, MD

    Hospital for Special Surgery, Weill Cornell Medicine
    New York, NY, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

This session will review immune checkpoint inhibitor (ICI) associated inflammatory arthritis and myositis, ICI use in patients with underlying RA, and some general treatment principles for rheumatic side effects of ICI.

Learning Objectives:

  • Recognize immune checkpoint inhibitor (ICI) associated arthritis.
  • Understand the relationship between ICI-myositis and ICI-myocarditis
  • Understand the relationship between DMARD treatment and survival in ICI-treated cancer patients.